Clinical Trial Detail

NCT ID NCT03572634
Title Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Tolero Pharmaceuticals, Inc.
Indications

CLL/SLL

Therapies

Dubermatinib

Dubermatinib + Ibrutinib

Age Groups: adult senior

No variant requirements are available.